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Background: Low-molecular-weight heparins (LMWHs) are safe and effective anticoagulant options for
cardiovascular patients when applied as body weight-adjusted doses. However, there are some barriers that make it
difficult to implement weight-adjusted doses in clinical practice. Therefore, it is vital to learn the dosing practices of
LMWH and its efficacy and safety in clinical practice.
Methods: A retrospective study was conducted in cardiovascular inpatients who had received at least one dose of
LMWH during a 6-month period. Appropriateness of LMWH dosing was determined and major clinical outcomes
(major adverse vascular events and major bleeding) during hospitalization were evaluated.
Results: A total of 376 admissions representing 364 patients received LMWH treatment. Of these, 17.0% (64/376) of
admissions did not have body weight records. Of the 312 admissions included for the outcome study, only 34
cases (10.9%) received the recommended doses of LMWH, while 51 cases (16.3%) received mild underdoses, 223
cases (71.5%) received major underdoses and 4 (1.3%) received excess doses. There were 10 major adverse vascular
events, which occurred more often in patients receiving excess doses of LMWH than in patients receiving
recommended, mild or major underdoses (50%, 2.9%, 2.0% and 2.7%, respectively, P < 0.001). After multivariable
analysis, severe renal insufficiency was an independent risk factor for major adverse vascular events [odds ratio (OR),
31.93; 95% confidence interval (CI), 5.99-170.30; P < 0.001]. No major bleeding was recorded.
Conclusions: Underdose of LMWH is commonly used in cardiovascular inpatients, which was suboptimal according
to guidelines. Using LMWH at a fixed, low dose for treatment purposes in patients without severe renal
insufficiency was not associated with a higher risk of adverse vascular events in the current study, though larger
studies with extended follow-ups are required to fully assess the long-term consequences of LMWH underdosing.
Keywords: Low molecular weight heparin, Dosing practice, Cardiovascular inpatients, Efficacy, SafetyBackground
Cardiovascular diseases are the leading cause of morbid-
ity and mortality in the world. Thrombosis is the final
biological evolution of the atherosclerotic process, which
promotes the development and progression of cardiovas-
cular diseases [1]. In recent years several clinical trials
have established, that low molecular weight heparins* Correspondence: haibindai@zju.edu.cn
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reproduction in any medium, provided the or(LMWHs) are safe and effective anticoagulant options
for patients with venous thromboembolism (VTE), acute
coronary syndrome (ACS), pulmonary embolism, un-
stable angina and non-ST-segment elevation myocardial
infarction [2-5]. This is partly due to the fact that
LMWHs have superior pharmacokinetic properties as
compared to unfractionated heparin (UFH) and without
the need for routine coagulation tests [6]. Therefore,
LMWHs have replaced UFH in most situations [7]. How-
ever, LMWHs have a longer half-life than UFH, with no
potential for full reversal. Thus, if an excess dose ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Study design and flow chart. Abbreviations: LMWH, low
molecular weight heparin.
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ing outcome than UFH. LMWHs are typically adminis-
tered for embolism therapy, based on body weight,
creatinine clearance and age (≥75 years) [6]. Appropriate
dosing of LMWH is vital for its efficacy and safety. Previ-
ous data have shown a relationship between LMWH
dose, the intensity of anticoagulation and incidence of
major hemorrhage, including intracranial bleeding [8].
However, there are some barriers existing in “real
world” clinical practice that make adherence to weight-
adjusted doses, according to the dose-finding trials dif-
ficult [9-11]. First, accurate weight assessment is a
challenge for seriously ill patients. Second, due to the
high concentration of pre-filled doses of LMWH, precise
measurement of a weight-based dose is difficult; this
could lead to an increase in medical errors and drug
waste [12]. Third, patients in real-world cardiovascular
units tend to be older, have more comorbidity and are
taking more prescribed drugs compared with those in
clinical trials [13]. Therefore, in China, some cardiolo-
gists tend to use a lower, fixed dose of LMWH relative to
the dose suggested by Chinese guidelines and recom-
mended from the clinical trials, to reduce the perceived
risk of hemorrhage and to simplify the dosing regimen.
However, to our knowledge, the efficacy and safety of this
“real word” clinical practice has not yet been studied.
In this retrospective study from a Chinese teaching
hospital, we examined the dosing practice of LMWHs,
and then determined the efficacy and safety of this prac-
tice in cardiovascular inpatients discharged from Jan 1 to
Jun 30, 2010.Table 1 Three types of low-molecular-weight heparins
used
Drug Recommended usage Individual adjustment
Enoxaparin 100 IU/kg,
every 12 h
1. 75% of the recommended
dose, every
12 hours (age ≥75 years);









This study was conducted in a general, university-
affiliated, teaching hospital with 2,200 licensed inpatient
beds, and approximately 77,000 admissions per year.
Using an electronic medical records database, the pa-
tients that were > 18 years of age and who were dis-
charged from cardiovascular wards between Jan 1 to Jun
30, 2010 were selected. Multiple admissions of a single
patient were counted as separate events. An admission
was excluded if the patient did not receive any LMWH
agents, received a single dose of LMWH, or had no
weight record (Figure 1). The study protocol was ap-
proved by the medical ethics committee of the Second
Affiliated Hospital, Zhejiang University School of Medi-
cine, China (No. 2012–37).
Three types of LMWHs were used in this hospital:
ClexaneW (Enoxaparin Sodium Injection, Aventis Inter-
continental, 0.4ml: 4000AxaIU), FraxiparineW (Nadro-
parin Calcium Injection, GlaxoSmithKline Inc, 0.4ml:
4100AxaIU), and FragminW (Dalteparin Sodium Injection,Pfizer Inc, 0.2ml: 5000AxaIU) (Table 1). All LMWHs were
administered by nurses during the hospitalization.
Data collection and definition
A chart review was conducted for each patient included
in the study. Data included basic patient demographics
(gender, age, weight, and height), clinical parameters
(blood creatinine, diagnosis and treatment), dosage of
LMWH, and clinical outcomes (major adverse vascular
events and major bleeding) during the hospitalization.
The body-mass index (BMI) was calculated by dividing
the individual’s weight (in kg) by the square of his or her
height (in meters). Hypertension was determined by
blood pressure > 140/90 mmHg or current use of anti-
hypertensive medication. Severe renal insufficiency (RI)
was determined by creatinine clearance <30 ml/min. Cre-
atinine clearance was estimated by the Cockcroft-Gault
equation [140 - age (years)] × weight (kg) × (0.85 if
female) / [72 × serum creatinine (mg/dl)]. Medication
orders were evaluated with the initial dose prescribed.
Dosing errors were determined strictly on the initial
mg/kg/dose. Interval frequency for LMWH was also
collected, which was adjusted by creatinine clearance.
The recommended LMWH dosage was defined in ac-
cordance with product package inserts (Table 1). Because
clinical evidence of dosing strategies for nadroparin and
dalteparin in patients with RI and elderly patients (≥75
years) are limited, we used the dosing strategies recom-
mended from the data on the use of enoxaparin [14].
Table 2 Patient and treatment characteristics
Patient characteristics Data
Age, y 63.8 ± 11.4
≥75 years, n (%) 65 (20.8)
Female, n (%) 77 (24.7)
Body mass index 23.8 ± 3.2








Atrial fibrillation 67 (21.5)
Deep vein thrombosis 9 (2.9)
Concurrent medical conditions, n (%)
Hypertension 194 (62.2)
Diabetes mellitus 69 (22.1)
Severe renal insufficient, n (%) 7 (2.2)
Creatinine clearance, ml/min 83.1 ± 27.8
Treatment variables, n (%)
Cardiac catheterization 26 (8.3)
Percutaneous coronary intervention 195 (62.5)
Radiofrequency catheter ablation 44 (14.1)
Length of hospital stay, d 8.9 ± 5.8
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recommended dose, and excess dose. An underdose or
excess dose was defined as ≤90% or ≥110% of the recom-
mended dose (in mg/kg/day), respectively. The under-
dose was further divided into mild underdose (≤90% but
>80% of the recommended dose, in mg/kg/day) and
major underdose (≤80% of the recommended dose, in
mg/kg/day).
The efficacy and safety of clinical outcomes were eval-
uated by major adverse vascular events and major bleed-
ing, respectively. Major adverse vascular events were
defined as any of the following complications during
in-hospital: death, myocardial re-infarction, recurrent
angina, revascularization procedures, ischemic stroke,
peripheral or visceral embolism, recurrent deep vein
thrombosis or pulmonary embolism. Major bleeding
was defined as any intracranial hemorrhage, transfusion
of at least 2 units of packed red blood cells, or absolute
drop in hematocrit of at least 12%; these parameters
were similar to definitions used in other trials and
registries [15].
Statistical analyses
Continuous variables are reported as mean ± SD, and
categorical variables are reported as numbers (percent-
age). Significance was determined using χ2 tests for cat-
egorical variables and Student’s t-tests or one way analysis
of variance (ANOVA) for continuous data variables.
Independent predictors of major adverse vascular
events were identified by use of univariable and multi-
variable logistic regression analysis. Important baseline
characteristics such as age, gender, weight, creatinine
clearance, hypertension, diabetes mellitus and dosage
subgroup of LMWH were entered into the model. The
odds ratio (OR) and corresponding 95% confidence
interval (CI) were reported for each variable in the
model. Variables were retained in the final multivariable
model if their level of significance was ≤0.05.
Results
Patient characteristics
A total of 19.5% (376/1,924) of admissions representing
364 patients in the cardiovascular units received LMWH
during this period. Of these, 17.0% (64/376) were lacking
body weight records. Thus 312 admissions were ana-
lyzed for outcome analysis. Of these, 4.8% (15/312) were
treated with dalteparin, 24.4% (76/312) were treated with
enoxaparin, and 70.8% (221/312) were treated with
nadroparin. As shown in Table 2, the mean age of pa-
tients was 64 ± 11 years, (75.3% were men). More than
half of the patients (58.6%) received LMWHs for the
treatment of unstable angina and non ST-segment eleva-
tion myocardial infarction. Of the 67 atrial fibrillation
patients, 7 (10.4%) had valvular heart disease (mitralstenosis or prosthetic heart valves) and had used war-
farin prior to hospitalization. Of the other 60 atrial fib-
rillation patients, only 2 had used warfarin prior to
hospitalization although there were 30 cases identified
as at “high risk” of stroke (defined as CHA2DS2-VASc
score ≥ 2) [16]. Seven patients (2.2%) with stage 4
chronic kidney disease (CKD) received LMWH treatment.
LMWH dosing practices
As shown in Table 3, only 34 cases (10.9%) received the
recommended dose of LMWH, 51 cases (16.3%) received
mild underdoses, 223 cases (71.5%) received major
underdoses, and 4 cases (1.3%) received excess doses.
There were no statistically significant differences in gen-
der, diagnosis or comorbid diseases, such as hyperten-
sion and diabetes mellitus among these groups. Patients
receiving excess doses of LMWH were older, weighed
more, had a poorer renal function, longer administration
duration and hospital stays than the patients receiving
the recommended dose (P < 0.05). Patients receiving
major underdoses of LMWH were younger and weighted
more than the patients receiving the recommended doses
(P < 0.05). None of the patients in underdoses groups
had severe RI. Major adverse vascular events occurred
more often in patients receiving excess doses of LMWH
than in patients receiving recommended, mild or major










Age, y 62.1 ± 10.7 67.0 ± 11.3 68.6 ± 12.8 77.0 ± 17.5 <0.001
≥75 years, n (%) 24 (10.8) 19 (37.3) 19 (55.9) 3 (75) <0.001
Female, n (%) 60 (26.9) 10 (19.6) 6 (17.6) 1 (25) 0.531
Weight (kg) 70.3 ± 9.2 58.2 ± 9.1 55.8 ± 8.8 71.5 ± 9.1 <0.001
BMI 24.7 ± 2.9 21.6 ± 2.6 21.0 ± 3.1 26.2 ± 3.1 <0.001
Diagnosis, n (%) 0.167
STEMI 37 (16.6) 9 (17.6) 6 (17.6) 1 (25)
UA/NSTEMI 126 (56.5) 34 (66.7) 21 (61.8) 2 (50)
Atrial fibrillation 54 (24.2) 6 (11.8) 7 (20.6) 0
DVT 6 (2.7) 2 (3.9) 0 1 (25)
Hypertension 134 (60.1) 34 (66.7) 23 (67.6) 3 (75) 0.668
Diabetes mellitus 53 (23.8) 7 (13.7) 9 (26.5) 0 0.267
Severe RI 0 0 3 (8.8) 4 (100) <0.001
Creatinine, mg/dl 0.8 ± 0.2 0.8 ± 0.2 1.0 ± 0.3 2.5 ± 1.0 <0.001
Creatinine clearance, ml/min 90.6 ± 26.8 69.7 ± 16.4 61.3 ±22.6 24.9 ± 5.0 <0.001
Administration duration, d 4.1 ± 2.1 3.9 ± 1.8 4.0 ± 1.6 6.5 ± 5.6 0.128
Length of hospital stay, d 8.8 ± 5.7 9.4 ± 5.8 8.2 ± 4.6 14.8 ± 16.8 0.179
Major adverse vascular events, n (%) 6 (2.7) 1 (2.0) 1 (2.9) 2 (50) <0.001
Abbreviations: LMWH, Low molecular weight heparin; BMI, body mass index; STEMI, ST-segment elevation myocardial infarction; UA/NSTEMI, Unstable angina/Non
ST-segment elevation myocardial infarction; DVT, Deep vein thrombosis; RI, renal insufficient.
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P < 0.001). No major bleeding was recorded in the whole
study population.Major adverse vascular events and risk factors
There were 10 major adverse vascular events (3.2%) in
this study, including four deaths, three myocardial re-
infarctions, two revascularization procedures and one is-
chemic stroke. Major adverse vascular events occurred
at 5.9 ± 9.0 days after admission. There was no differ-
ence in the major adverse vascular event rate when com-
paring different diagnoses (P > 0.05). Major adverse
vascular events occurred in 4 patients with ST-segment
elevation myocardial infarction (7.5%), 4 patients with
unstable angina/non ST-segment elevation myocardial
infarction (2.2%), 1 patient with atrial fibrillation (1.5%),
and 1 patient with deep vein thrombosis (11.1%). Uni-
variate analysis of the risk factors of major adverse vas-
cular events is presented in Table 4. Multivariable
analysis found that only one risk factor (severe RI) was
independently associated with an increased risk for
major adverse vascular events (OR, 31.93; 95% CI, 5.99-
170.30; P < 0.001), while age≥75 years, excess doses of
LMWH were not independent predictors of major ad-
verse vascular events.Discussion
In the present study we assessed LMWH dosing prac-
tices in 364 cardiovascular inpatients (376 admissions)
and identified the efficacy and safety of LMWH treat-
ment in 312 cases as measured by major adverse vascu-
lar events and major bleeding. There is a considerable
disparity in LMWH use when comparing clinical prac-
tice to the guideline [6]. Seventeen percent of patients
(64/376) without body weight records received LMWH,
10.9% (34/312) of patients received the recommended
doses of LMWH and 87.8% (274/312) received under-
doses of LMWH. Interestingly, we found that receiving
underdoses of LMWH was not a risk factor for major
adverse vascular events. The only risk factor for major
adverse vascular events was severe RI.
LMWHs are prescribed based on the patient’s weight
according to dose-finding studies. However, accurate
weight assessment is a challenge for seriously ill patients
that are due to the limitations of resources, physical
space and time [17]. In our study, we found that ap-
proximately 1 in 6 patients received LMWHs without
having a record of weight. This is similar to a previous
study reported that approximately 1 in 10 patients
received enoxaparin for treatment of an ACS without
weight documentation [13]. Furthermore, it has been
reported that estimation of patients’ weights by health
Table 4 Risk factors for major adverse vascular events (univariable analysis)







Age, ≥75 y 60 (20) 5 (50) 4.03 (1.13-14.38) 0.036
Female 72 (24) 5 (50) 3.19 (0.90-11.35) 0.071
Weight, >60 kg 235 (78) 10 (100) – 0.086
STEMI 49 (16) 4 (40) 3.44 (0.94-12.65) 0.071
Hypertension 186 (62) 8 (80) 2.50 (0.52-11.95) 0.201
Diabetes mellitus 69 (23) 0 – 0.079
Severe RI 4 (1.3) 3 (30) 31.93 (5.99-170.30) 0.001
Inappropriate dose 269 (89) 9 (90) 1.104 (0.14-8.99) 0.701
Excess dose 2 (0.7) 2 (20) 37.5 (4.68-300.75) 0.005
Underdose 267 (88) 7 (70) 0.306 (0.08-1.24) 0.109
Major underdose 217 (72) 6 (60) 0.588 (0.162-2.134) 0.310
Abbreviations: STEMI, ST-segment elevation myocardial infarction; RI, renal insufficient; OR, odds ratio; CI, confidence interval.
*Reference groups include age<75 years, male, weight ≤60 kg, no STEMI, no hypertension, no diabetes mellitus, no severe RI, recommended dose, no excess dose,
no underdose, no major underdose.
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10 kg [18]. Inappropriate dosing of LMWH can easily
occur if the weight is estimated incorrectly, which can
lead to medication errors in clinical practice. However,
studies of the consequences of inappropriate dosing of
LMWHs in real world practices are still scarce.
The major complication of anticoagulant and throm-
bolytic therapy is bleeding. A previous study demon-
strated that patients with ACS often received excess
doses of LMWH that was accompanied by an increased
risk of major bleeding [15]. In order to decrease the risk
of bleeding, some clinicians in China often prefer to
choose empirical dose strategies when administering
LMWHs instead of those reported in the results of clin-
ical trials or suggested by Chinese guidelines. In our hos-
pital, the most commonly adopted dosing strategies are
enoxaparin 4,000AxaIU, nadroparin 4,100AxaIU or dal-
teparin 5,000AxaIU given twice daily when a patient’s
weight is < 80 kg. For patients that weigh ≥ 80 kg, enox-
aparin 6,000AxaIU, nadroparin 6,200AxaIU or dalteparin
7,500AxaIU are given twice daily. These dosing strat-
egies reflected the reason for the high rate of LMWH
underdosing in the current study. As a result, there were
no major bleeding events in our study; conversely, the
rate of major bleeding events has been found to be ap-
proximately 1–6.5% in clinical trials of LMWHs [9-11].
Therefore, the practice of underdosing LMWH done in
our hospital appears to be safe.
Unlike excess dosing of LMWH, which is related to a
risk of bleeding, foremost concern associated with un-
derdose of LMWH is the risk of embolism. Thus, we
determined the efficacy of the current dosing practice of
LMWHs, as measured by the incidence of embolism.Surprisingly, in the underdose LMWH group, the inci-
dence of major adverse vascular events was similar to
that of the group receiving the recommended dose (2.6%
vs. 2.9%). Previous data have demonstrated that patients
with low anti-Xa activity increased 30-day mortality [19].
This may be due to the fact that the underdose of
LMWH in our study doesn’t indicate low anti-Xa activity
as LMWH has linear pharmacokinetics but high between-
subject variability [20,21]. On the other hand, clinical
outcomes are also influenced by patients’ characteristics
and not only the dosage of LMWH. In the above men-
tioned study, patients with sub-therapeutic anti-Xa levels
were significantly older, and had more impaired renal
function and inferior heart function compared with
others [19]. However, in our study, patients that received
underdoses of LMWH had better baseline characteristics
(younger and better renal function) than the recom-
mended and excess dose groups; this may be the primary
reason that the underdosing of LMWH was not found to
be a risk factor for embolism in our study.
Since there were no severe RI patients receiving un-
derdoses of LMWH, a fixed and weight-independent
dosage may be not suitable for severe RI patients.
LMWHs are not recommended for use in patients with
severe RI due to the risk of accumulation may lead to
major bleeding [11,22,23]. According to the results of the
ExTRACT-TIMI 25 trial [11], a dose of 1 mg/kg of enox-
aparin every 24 h was recommended for patients with an
estimated creatinine clearance <30 ml/min. However, in
our study, major adverse vascular events occurred more
often in severe RI patients than in patients with creatine
clearance ≥30 ml/min (30% vs. 1.3%, P < 0.001), although
57.1% (4/7) of severe RI patients receiving excess doses
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severe RI is the only predictor of major adverse vascular
events. In elderly patients (≥75 years), STEMI patients,
excess doses of LMWH were not independent predictors
of major adverse vascular events. Results from the
current study are consistent with those from previous
studies in which patients with RI have a higher risk for
thromboembolic complications [24-26], and support the
recommendation for dose adjustments based on anti-Xa
activity and not calculated based on a simple dose
scheme for LMWH used in RI patients [27]. Our results
indicate that using LMWH at a fixed, lower dose in
patients without severe RI may be safe and effective.
Nevertheless, there are some limitations to this study.
First, our findings are based on the results of a one-
center, retrospective study, complementing the prospect
and lack of follow-up. Second, unlike randomized trials
that have more restrictive inclusion criteria, it must be
noted that the patient characteristics in this study were
not as well-controlled. Third, due to a lack of anti-Xa
assay in our hospital, we could not measure anti-Xa
activity in RI patients. Finally, small sample size is a
potential limiting factor in this study as well.
Conclusions
In summary, the current study demonstrated that under-
dose of LMWH is commonly used in cardiovascular
inpatients. Using LMWH in a fixed, lower dose for treat-
ment purposes in patients without severe RI was not
associated with a high risk of adverse vascular events in
our study. Larger studies with extended follow-ups are
required to fully assess the long-term consequences of
LMWH underdosing.
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